

INOVIO PHARMACEUTICALS, INC.  
Form 8-K  
July 23, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) July 23, 2014**

**INOVIO PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-14888**  
**(Commission**  
  
**File Number)**

**33-0969592**  
**(I.R.S. Employer**  
  
**Identification No.)**

**660 West Germantown Pike, Suite 110**

**Plymouth Meeting, Pennsylvania**  
**(Address of principal executive offices)**

**19462**  
**(Zip Code)**

**Registrant's telephone number, including area code: (267) 440-4200**

**1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, Pennsylvania 19422**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On July 23, 2014, the Company supplemented the information included in its press release issued earlier today by announcing through an electronic media statement that per protocol analysis measured subjects who received 3 doses of a 3-dose regimen; an ITT (intent-to-treat analysis) also achieved statistical significance.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

By: /s/ Peter Kies  
Peter Kies,

Chief Financial Officer

Date: July 23, 2014